We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical placed 246 da Vinci 5 systems as the installed base topped 1,700 systems.
ISRG began rolling out the first of 100-plus software updates and filed new FDA 510(k) features.
Intuitive Surgical expects da Vinci 5 upgrades to build over years, similar to the da Vinci Xi cycle.
Intuitive Surgical's (ISRG - Free Report) second-quarter 2026 results suggest that the da Vinci 5 platform is evolving into more than a routine product refresh. It appears to be laying the foundation for a multi-year capital upgrade cycle driven by software innovation, clinical capabilities and a growing installed base.
The momentum was evident in the quarter's capital performance. Intuitive Surgical placed 468 da Vinci systems globally, including 246 da Vinci 5 systems, while the installed base of the latest-generation platform surpassed 1,700 systems. More than 15,000 surgeons have already used da Vinci 5 since its launch, indicating rapid physician adoption that could encourage additional hospitals to modernize their robotic surgery programs. Trade-ins also accelerated to 144 systems from 83 a year earlier, largely reflecting U.S. customers upgrading from older platforms.
Unlike previous hardware-centric product launches, da Vinci 5 has been designed as a software-enabled platform capable of continuous enhancements. During the quarter, Intuitive Surgical rolled out the first phase of more than 100 planned software updates focused on telepresence, simulation-based training and care-team workflow. The company also submitted multiple new features for FDA 510(k) clearance, reinforcing management's strategy of steadily expanding the platform's capabilities rather than relying on a single launch event.
Management also drew parallels with the successful da Vinci Xi upgrade cycle. The Xi transition required roughly seven years to reach peak trade-in volumes, and executives expect the da Vinci 5 upgrade cycle to follow a similarly progressive, multi-year path. As software updates continue to enhance the ecosystem, management believes the platform will become increasingly attractive to existing customers over time.
Notably, hospitals continue to invest despite macroeconomic concerns. Management described the U.S. capital environment as stable, with a healthy pipeline supported by leasing, which accounts for roughly 70% of U.S. system acquisitions. The company noted that customer interest in accessing the latest da Vinci 5 technology, higher utilization and additional system capacity have outweighed concerns surrounding healthcare reimbursement and broader economic uncertainty.
Peer Updates
Edwards Lifesciences (EW - Free Report) is positioning itself for a multi-year product upgrade cycle through continuous innovation across its structural heart portfolio rather than relying on a single platform. Management highlighted several near-term catalysts, including the next-generation SAPIEN X4S platform currently in the ALLIANCE trial, an anticipated U.S. TAVR National Coverage Determination update, new PASCAL Capture Clarity technology, a U.S. tricuspid indication for PASCAL, the rollout of ECLIPTIS, and continued expansion of EVOQUE and SAPIEN M3.
The company believes these product launches, indication expansions and growing clinical evidence will gradually broaden patient access, reinforce physician adoption and support durable product refresh cycles and long-term structural heart growth.
Glaukos (GKOS - Free Report) is building a long-term upgrade cycle through a diversified ophthalmology pipeline spanning multiple therapeutic platforms. While iDose TR and Epioxa remain the company's primary commercial growth engines, management is advancing iDose TREX, iDose TRIO, a keratoconus screening device, third-generation customized iLink therapy, PRESERFLO MicroShunt, additional iStent infinite indications, an iLution therapy for Demodex blepharitis and GLK-401 for retinal disease.
The company also continues expanding Phase IV clinical evidence and commercial infrastructure to support adoption. Management believes that its pipeline programs can create successive innovation cycles, expand treatment paradigms and sustain growth well into the next decade.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 33.8% so far this year compared with a 10.7% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 32.74X, above the industry average. But, it is significantly lower than its five-year median of 69.11X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?
Key Takeaways
Intuitive Surgical's (ISRG - Free Report) second-quarter 2026 results suggest that the da Vinci 5 platform is evolving into more than a routine product refresh. It appears to be laying the foundation for a multi-year capital upgrade cycle driven by software innovation, clinical capabilities and a growing installed base.
The momentum was evident in the quarter's capital performance. Intuitive Surgical placed 468 da Vinci systems globally, including 246 da Vinci 5 systems, while the installed base of the latest-generation platform surpassed 1,700 systems. More than 15,000 surgeons have already used da Vinci 5 since its launch, indicating rapid physician adoption that could encourage additional hospitals to modernize their robotic surgery programs. Trade-ins also accelerated to 144 systems from 83 a year earlier, largely reflecting U.S. customers upgrading from older platforms.
Unlike previous hardware-centric product launches, da Vinci 5 has been designed as a software-enabled platform capable of continuous enhancements. During the quarter, Intuitive Surgical rolled out the first phase of more than 100 planned software updates focused on telepresence, simulation-based training and care-team workflow. The company also submitted multiple new features for FDA 510(k) clearance, reinforcing management's strategy of steadily expanding the platform's capabilities rather than relying on a single launch event.
Management also drew parallels with the successful da Vinci Xi upgrade cycle. The Xi transition required roughly seven years to reach peak trade-in volumes, and executives expect the da Vinci 5 upgrade cycle to follow a similarly progressive, multi-year path. As software updates continue to enhance the ecosystem, management believes the platform will become increasingly attractive to existing customers over time.
Notably, hospitals continue to invest despite macroeconomic concerns. Management described the U.S. capital environment as stable, with a healthy pipeline supported by leasing, which accounts for roughly 70% of U.S. system acquisitions. The company noted that customer interest in accessing the latest da Vinci 5 technology, higher utilization and additional system capacity have outweighed concerns surrounding healthcare reimbursement and broader economic uncertainty.
Peer Updates
Edwards Lifesciences (EW - Free Report) is positioning itself for a multi-year product upgrade cycle through continuous innovation across its structural heart portfolio rather than relying on a single platform. Management highlighted several near-term catalysts, including the next-generation SAPIEN X4S platform currently in the ALLIANCE trial, an anticipated U.S. TAVR National Coverage Determination update, new PASCAL Capture Clarity technology, a U.S. tricuspid indication for PASCAL, the rollout of ECLIPTIS, and continued expansion of EVOQUE and SAPIEN M3.
The company believes these product launches, indication expansions and growing clinical evidence will gradually broaden patient access, reinforce physician adoption and support durable product refresh cycles and long-term structural heart growth.
Glaukos (GKOS - Free Report) is building a long-term upgrade cycle through a diversified ophthalmology pipeline spanning multiple therapeutic platforms. While iDose TR and Epioxa remain the company's primary commercial growth engines, management is advancing iDose TREX, iDose TRIO, a keratoconus screening device, third-generation customized iLink therapy, PRESERFLO MicroShunt, additional iStent infinite indications, an iLution therapy for Demodex blepharitis and GLK-401 for retinal disease.
The company also continues expanding Phase IV clinical evidence and commercial infrastructure to support adoption. Management believes that its pipeline programs can create successive innovation cycles, expand treatment paradigms and sustain growth well into the next decade.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 33.8% so far this year compared with a 10.7% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 32.74X, above the industry average. But, it is significantly lower than its five-year median of 69.11X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.